NU 2022-184 INVENTORS
SHORT DESCRIPTION
This technology facilitates the rapid expression and conjugation of therapeutic proteins to nanoparticles, creating highly specific drug delivery systems that can be generated swiftly and cost-effectively. BACKGROUND
In recent years, there has been significant advancement in biomolecular tools, including the use of nanoparticles for drug delivery. While these have shown promise, particularly in cancer therapies and COVID-19 vaccines, challenges remain, such as the rapid clearance from the body and non-specific delivery. Current nanoparticle systems, such as liposomes, have been used but often lack the precision needed for targeted therapeutic applications. ABSTRACT
This technology presents an innovative method for the rapid generation of protein-conjugated nanoparticles using cell-free protein expression systems. This approach overcomes current limitations by enabling the specific delivery of therapeutic cargo, including small molecules, proteins, and nucleic acids, to targeted tissues and cells. By employing various conjugation methods and particle types, the technology supports the development of diverse therapeutic nanoparticles. This versatile platform not only enhances the delivery accuracy but also significantly reduces production time, facilitating on-demand manufacturing and rapid therapeutic development. APPLICATIONS
Specific delivery of gene editing cargo (Cas9)
More specific vaccines (delivery of mRNA, adjuvants)
In vivo cell engineering (generation of CAR-Ts)
Organ and Tissue-specific delivery of therapeutic cargo
ADVANTAGES
Reduces time required for generating large number of therapeutic nanoparticles.
No purification required
PUBLICATIONS
Justin A. Peruzzi, Timothy Q. Vu, Taylor F. Gunnels, Neha P. Kamat, "Rapid Generation of Therapeutic Nanoparticles Using Cell-Free Expression Systems," Small Methods, 28 April 2023.
IP STATUS
PCT Patent Application Filed.